December 15, 2021 -- Opentrons' subsidiary Neochromosome and Mekonos have formed a new partnership to advance cell engineering for personalized cell therapies.
The partnership will test and optimize the delivery of Neochromosome's de novo synthesized Big-DNA cargo directly into the nuclei of human-induced pluripotent stem cells using Mekonos' proprietary Iris technology. The companies' cell-based therapies have the potential to treat a variety of diseases, including diabetes, Parkinson's, and cancer, both companies said.
The research collaboration launches in January 2022 in the San Francisco Bay Area, with initial results expected mid-year.
No financial agreements were disclosed.
Copyright © 2021 scienceboard.net